Approval · Notice of Compliance 27702 · 2022
CONTRAVE: Notice of Compliance 27702
Issued March 3, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27702
- Date
- March 3, 2022
- Company
- Bausch Health, Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph. Conversion of the Product Monograph to 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CONTRAVE | Not yet assigned | — |
Medicinal ingredients
- NALTREXONE HYDROCHLORIDE 8 MG per TAB
- BUPROPION HYDROCHLORIDE 90 MG per TAB